A Collaborative Fight Against Ovarian Cancer
The ultimate goal is an early diagnostic test for ovarian cancer and better, more effective treatment plan for those suffering from ovarian cancer.
Cancer research at the Ovarian Cancer Institute is directed by Chief Research Officer, Dr. John McDonald, at his state-of-the-art laboratory on the campus of the Georgia Institute of Technology in Atlanta. Here, cutting-edge discoveries in molecular cancer biology are combined with Georgia Tech’s strengths in analytical chemistry, computational sciences, and nanotechnology. Because of this collaboration, our support for this laboratory sets us apart from the “traditional cancer research institute.”
To advance cancer research, patients have volunteered to provide medical history information and tissue and serum samples. Because the medical offices are located just a few miles from the lab, samples were collected by Dr. Benedict Benigno, OCI’s founder and CEO, and were immediately flash-frozen and transported to the cancer research laboratory. Due to the pristine tumor samples and the availability of medical histories, the Ovarian Cancer Institute-funded laboratory has established a highly comprehensive ovarian cancer research program that is unique to any other in the U.S. or the world. As a result, the lab supported by the Ovarian Cancer Institute is home to one of the largest tissue and serum banks and ovarian cancer patient-history databases in the world.
Ovarian Cancer Institute researchers are having a significant impact in two areas of cancer biology: Diagnostics and Therapeutics.
Early Diagnostic Test: Detecting Ovarian Tumors in Stage I Instead of Stage III or IV: Scientists supported by the Ovarian Cancer Institute have discovered and developed a novel, 100% sensitive and specific, early diagnostic test for ovarian cancer. This unique test detects metabolites in a woman’s ovary tissues at the molecular level, so we can identify cancer in the first stage of its development. With this test, doctors may diagnose ovarian cancer in a woman before the tumor can grow, spread, and damage other tissues.
More Stage I ovarian cancer samples are needed to fully validate this test and bring it to the women who need it. Early ovarian cancer samples are difficult to come by, as ovarian cancer typically is not diagnosed until later in the disease process.
Your financial support can help acquire these rare samples, further validate this novel diagnostic testing approach, and make this test available to women who are at higher risk for ovarian cancer. This test would allow physicians to screen women at risk at annual exams, so ovarian cancer can be diagnosed very early, when it is far more treatable.
More Targeted, Less Toxic Therapy: Scientists supported by the Ovarian Cancer Institute have also developed and are currently testing a nanoparticle system that delivers therapeutic RNA directly to the cancer cells in a woman’s ovarian tumor, sparing her the toxicity of traditional chemotherapy or radiation therapy.
In early tests, this innovative treatment has successfully eradicated ovarian cancer. More importantly, by delivering the medicine directly to the cancer cells, our technique spares healthy cells and tissues, unlike chemotherapy. This is a bold advance in the field of precision medicine. With your support, scientists can expand tests of this RNA-based technique to validate its effectiveness.
Current chemotherapy and radiation regimens cause devastating physical side effects in women with ovarian cancer. It doesn’t have to be this way. We support the development of highly targeted, nanotechnology-driven delivery methods for cancer-fighting drugs.
Truly Personalized, Optimal Drug Therapy: Machine learning systems allow scientists to test and validate huge amounts of data with speed and accuracy unreachable by human power alone. Scientists funded by the Ovarian Cancer Institute have developed and tested a new treatment algorithm for ovarian cancer. It will help doctors accurately predict which chemotherapy product a particular patient’s cancer will respond to – based on her own DNA.
This algorithm, tested and refined by machine learning, allows a physician to target single or multiple malfunctioning genes unique to each patient. With this information, a woman’s doctor could prescribe the correct medicine, instead of using the only methods currently available, “trial and error.” Results from early trials conducted at Northside Hospital in Atlanta have been promising.
At the Ovarian Cancer Institute, we support research to make truly customized, personalized medicine possible, and to treat ovarian cancer much earlier. With your support, scientists can expand necessary clinical trials and validation tests. You can help fund important research that will help women with ovarian cancer avoid life-threatening delays in finding an effective treatment – because oncologists will be able to unlock the clues in her DNA code that point to the drug most likely to fight her cancer.
Our goal is to fund necessary additional testing of these three technologies and prove their validity according to the most stringent, FDA-required standards.
Most importantly, our goal is to save women’s lives, creating a world where women with ovarian cancer can benefit from an early diagnosis and personalized, targeted therapy. We want women with ovarian cancer to have options that are far better than those available to them now – even at the most prestigious cancer treatment centers.
For more in-depth knowledge about OCI and the research CLICK HERE (appendix provided by request)
To learn more about our cancer research institute; our world renowned CEO and scientists; how to volunteer; or to attend one of our yearly fundraising events, contact the Ovarian Cancer Institute at 404-300-2997, or use our contact form.